Calquence (Acalabrutinib) is a targeted therapy used in the treatment of certain types of blood cancers. It belongs to a class of drugs known as BTK inhibitors, which act on cancer cells within the lymphatic system with high precision.
What is Calquence (Acalabrutinib)?
Calquence is part of the Bruton’s Tyrosine Kinase (BTK) inhibitors family, enzymes that play a key role in the growth and survival of certain abnormal blood cells.
In some blood cancers, BTK signaling becomes overactive, leading to uncontrolled cell growth. Calquence works by:
- Blocking abnormal cancer cell signaling
- Reducing the growth of malignant lymphocytes
- Helping control disease progression
In simple terms:
It targets the internal growth pathway of blood cancer cells.
Indications
Calquence (Acalabrutinib) is used in:
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Other lymphoid malignancies as per treatment protocols
Dosage and Administration
- Standard dose: 100 mg twice daily
- Taken orally
- Can be taken with or without food
- Must be taken consistently at the same times every day
- Treatment duration is determined by the physician based on response
Common Side Effects
May include:
- Headache
- Fatigue
- Diarrhea
- Mild bruising or bleeding
- Low blood cell counts
- Mild infections
Rarely: complications requiring close medical monitoring.
Availability & How to Access Treatment
Calquence (Acalabrutinib) is available through Macrocare’s approved partners.
You can now request and access the medication easily through us.
WhatsApp contact for medication requests:
Click here
Calquence (Acalabrutinib) Calquence (Acalabrutinib) 100 mg is an effective targeted therapy for blood cancers such as CLL and SLL, working by blocking cancer cell signaling and improving disease control.
Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified physician.
